国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2013年
8期
573-576
,共4页
夏建波%龚央央%柴协力%胡子民
夏建波%龔央央%柴協力%鬍子民
하건파%공앙앙%시협력%호자민
非小细胞肺癌%奥沙利铂%多西他赛%化疗
非小細胞肺癌%奧沙利鉑%多西他賽%化療
비소세포폐암%오사리박%다서타새%화료
Non small cell lung cancer%Oxaliplatin%Docetaxel%Chemotherapy
目的 本研究旨在评价多西他赛单药或联合奥沙利铂二线治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性.方法 将57例ⅢB期或Ⅳ期的一线治疗失败的NSCLC患者分成多西他赛联合奥沙利铂组(27例)(多西他赛60 mg/m2,第1天静脉输注+奥沙利铂100 mg/m2,第2天静脉输注)和多西他赛单药组(30例)(多西他赛75 mg/m2,第1天静脉输注),均为3周方案,每例患者接受2～6个周期治疗,评价疗效及不良反应.结果 联合治疗组和多西他赛单药组疾病控制率分别为70.4％和43.3％(P=0.04),中位无进展生存期分别为5.2个月和3.6个月(P=0.03),中位生存时间分别为9.8个月和7.2个月(P=0.06).而在主要的3～4级毒副反应中,联合治疗组和多西他赛单药组比较,差异均无统计学意义.结论 多西他赛联合奥沙利铂二线治疗NSCLC取得了较好的疗效,毒副反应可以耐受,值得进一步研究.
目的 本研究旨在評價多西他賽單藥或聯閤奧沙利鉑二線治療晚期非小細胞肺癌(NSCLC)的療效和安全性.方法 將57例ⅢB期或Ⅳ期的一線治療失敗的NSCLC患者分成多西他賽聯閤奧沙利鉑組(27例)(多西他賽60 mg/m2,第1天靜脈輸註+奧沙利鉑100 mg/m2,第2天靜脈輸註)和多西他賽單藥組(30例)(多西他賽75 mg/m2,第1天靜脈輸註),均為3週方案,每例患者接受2～6箇週期治療,評價療效及不良反應.結果 聯閤治療組和多西他賽單藥組疾病控製率分彆為70.4％和43.3％(P=0.04),中位無進展生存期分彆為5.2箇月和3.6箇月(P=0.03),中位生存時間分彆為9.8箇月和7.2箇月(P=0.06).而在主要的3～4級毒副反應中,聯閤治療組和多西他賽單藥組比較,差異均無統計學意義.結論 多西他賽聯閤奧沙利鉑二線治療NSCLC取得瞭較好的療效,毒副反應可以耐受,值得進一步研究.
목적 본연구지재평개다서타새단약혹연합오사리박이선치료만기비소세포폐암(NSCLC)적료효화안전성.방법 장57례ⅢB기혹Ⅳ기적일선치료실패적NSCLC환자분성다서타새연합오사리박조(27례)(다서타새60 mg/m2,제1천정맥수주+오사리박100 mg/m2,제2천정맥수주)화다서타새단약조(30례)(다서타새75 mg/m2,제1천정맥수주),균위3주방안,매례환자접수2～6개주기치료,평개료효급불량반응.결과 연합치료조화다서타새단약조질병공제솔분별위70.4％화43.3％(P=0.04),중위무진전생존기분별위5.2개월화3.6개월(P=0.03),중위생존시간분별위9.8개월화7.2개월(P=0.06).이재주요적3～4급독부반응중,연합치료조화다서타새단약조비교,차이균무통계학의의.결론 다서타새연합오사리박이선치료NSCLC취득료교호적료효,독부반응가이내수,치득진일보연구.
Objective To evaluate the efficacy and safety of docetaxel/oxaliplatin and docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC).Methods Fifty seven patients with previously treated advanced NSCLC had divided into docetaxel/oxaliplatin group (docetaxel 60 mg/m2 on 1st day with oxaliplatin 100 mg/m2 on 2nd day,every three weeks) and doxetaxel group (75 mg/m2 on 1st day,every three weeks).All patients who received 2-6 cycles could be evaluated.Results There were statistical differences between docetaxel/oxaliplatin group and docetaxel group in the disease control rate (70.4 ％ vs 43.3 ％,P=0.04),the median progression-free survival (5.2 months vs 3.6 months,P =0.03),but no statistical differences in the median overall survival (9.8 months vs 7.2 months,P =0.06).In addition,there were statistical differences in the main grade 3-4 toxicity between two groups.Conclusions Docetaxel/oxaliplatin is an effective and well tolerated scheme in the treatment of advanced NSCLC,which warrant further evaluation as second-line therapy for patients with NSCLC.
